Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: Protection by inhaled steroids

American Journal of Respiratory and Critical Care Medicine

Volumn 166, Issue 3, 2002, Pages 294-300

  De Kluijver, Josephine ^a   Evertse, Christine E ^a   Schrumpf, Jasmijn A ^a   Van Der Veen, Hilly ^a   Zwinderman, Aeilko H ^a   Hiemstra, Pieter S ^a   Rabe, Klaus F ^a   Sterk, Peter J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Airway hyperresponsiveness; Asthma; Eosinophils; Induced sputum; Inhaled steroids

Indexed keywords

ALLERGEN; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; INTERLEUKIN 5; MESSENGER RNA; METHACHOLINE; NITRIC OXIDE; PLACEBO; STEROID;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM EXPOSURE; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPUTUM ANALYSIS; STEROID THERAPY; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALLERGENS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; MALE; RESPIRATORY FUNCTION TESTS; RESPIRATORY TRACT DISEASES; SEVERITY OF ILLNESS INDEX;

EID: 0036682892     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2112097     Document Type: Article

References (46)

1. Global strategy for asthma management and prevention
2. Outcome of asthma: Longitudinal changes in lung function
3. Risk factors from childhood to adulthood for bronchial responsiveness at age 32-42 yr.
4. Airway inflammation in mild intermittent and in persistent asthma
5. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness
6. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission
7. The role of allergy in the development of asthma
8. Asthma and indoor exposure to allergens
9. Increase in non-specific bronchial responsiveness after repeated inhalation of low doses of allergen
10. Airway inflammation and altered alveolar macrophage phenotype pattern after repeated low-dose allergen exposure of atopic asthmatic subjects
11. Mild experimental exacerbations of asthma induced by individualised low-dose repeated allergen exposure: A double-blind evaluation
12. No signs of activity markers in peripheral blood despite increased bronchial reactivity after repeated low-dose allergen exposure
13. Increases in airway eosinophils and interleukin-5 with minimal bronchoconstriction during repeated low-dose allergen challenge in atopic asthmatics
14. Repeated aerosol exposure to small doses of allergen: A model for chronic allergic asthma
15. Repeated inhalation of low doses of cat allergen that do not induce clinical symptoms increases bronchial hyperresponsiveness and eosinophil cationic protein levels
16. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation
17. Effects of once daily dosing with inhaled budesonide on airway hyperresponsiveness and airway inflammation following repeated low-dose allergen challenge in atopic asthmatics
18. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids
19. The relationship between airways inflammation and asthma severity
20. Airway responsiveness: Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults
21. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine
22. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo
23. The relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects
24. Effect of methacholine challenge on cellular composition of sputum induction
25. Experimental rhinovirus 16 infection: Effects on cell differentials and soluble markers in sputum in asthmatic subjects
26. Diurnal variability - Time to change asthma guidelines?
27. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma
28. Bactericidal/permeability-increasing protein release in whole blood ex vivo: Strong induction by lipopolysaccharide and tumor necrosis factor-alpha
29. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
30. Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue
31. A human whole-blood assay for analysis of T-cell function by quantification of cytokine mRNA
32. Increased allergen-specific Th2 responses in vitro in atopic subjects receiving subclinical allergen challenge
33. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations
34. Cytokine mRNA expression in patients with mild allergic asthma following low dose or cumulative dose allergen provocation
35. Eosinophilopoiesis in a murine model of allergic airway eosinophilia: Involvement of bone marrow IL-5 and IL-5 receptor alpha
36. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma
37. Prolonged allergen exposure induces structural airway changes in sensitized rats
38. Airway inflammation is present during clinical remission of atopic asthma
39. Repeated allergen challenge as a new research model for studying allergic reactions
40. Reduced late asthmatic response by repeated low-dose allergen exposure
41. An improved murine model of asthma: Selective airway inflammation, epithelial lesion and increased methacholine responsiveness following chronic exposure to aerosolised allergen
42. Bronchial hyperresponsiveness and airway wall remodelling induced by exposure to allergen for 9 weeks
43. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide
44. Acute and chronic effects of allergic airway inflammation on pulmonary nitric oxide production
45. Time course of inflammatory and remodeling events in a murine model of asthma: Effect of steroid treatment
46. Fluticasone inhibits but does not reverse allergen-induced structural airway changes